Existing studies have contributed a strong evidence to demonstrate that a high tumor burden mutation (TMB) was correlated with the increasement of infiltrating CD8+ T cells, which recognized tumor neoantigens then resulted in intense tumor-killing effects to annihilate tumor cells (31–33).Thus, we speculated that TMB might act as a prognostic factor of responsiveness to antitumor immunotherapy and aimed to investigate the potential interaction between the ICI scores and TMB to uncover the hereditary variations of the ICI score subtype. The gene discussed is CD8A; the disease is neoplasm.